Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Inclusion criteria

• ✓Eastern Cooperative Oncology Group (ECOG) performance status score 0-1 Histologically confirmed non-small cell lung cancer, clinical stage IIB (tumors ≥4cm), II, IIIA (lymph nodes limited to N1) according to the UICC lung cancer staging system (8th edition).
• ✓. Blood routine (within 14 days before the first study treatment without receiving hematopoietic stimulating factors or blood transfusions): absolute neutrophil count (ANC) ≥ 1.5 × 109/L, absolute lymphocyte count (LC) ≥ 0.5 × 109/L; platelet count (PLT) ≥ 100 × 109/L, hemoglobin (Hb) ≥ 90g/L
• ✓. Liver function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 xULN; total bilirubin (TBIL) ≤1.5 x ULN (for patients with confirmed Gilbert syndrome, total bilirubin ≤3.0 mg/dL); albumin (ALB) ≥3 g/dL;
• ✓. Renal function: creatinine clearance rate (CrCl) ≥45mL/minute (using the Cockcroft-Gault formula);
• ✓. Coagulation function: international normalized ratio (INR) ≤1.5, activated partial thromboplastin time (APTT) ≤1.5 x ULN;
• ✓. Cardiac color Doppler ultrasound examination: left ventricular ejection fraction (LVEF) ≥50% Age and fertility status Age ≥18 and ≤75. Women of childbearing age (WOCBP) must have a negative serum or urine pregnancy test within 24 hours before starting the study treatment (the minimum sensitivity of HCG is 25 IU/L or equivalent units).